Alpha Cognition Inc. has announced positive preclinical data for their drug candidate ALPHA-1062, designed for the treatment of mild traumatic brain injury (mTBI) resulting from repetitive blast trauma, a condition prevalent among military personnel. The study, supported by the US Department of Defense and conducted in collaboration with the US Department of Veterans Affairs and the Seattle Institute of Biomedical and Clinical Research, has concluded. The data indicates that ALPHA-1062 administration leads to a reduction in neuropathological indices associated with TBI. Furthermore, the drug demonstrated additional benefits, including reductions in neuroinflammation and increased nerve growth factor receptor expression. These findings support the continued development of ALPHA-1062, with future steps involving formulation for sublingual administration and further pharmacokinetic studies.